Renal Ventures Management Receives $30M Investment from Goldman Sachs
Renal Ventures Management, LLC, a Denver, CO-based renal care provider that operates 25 dialysis centers in six states, has received $30m in capital from Goldman Sachs Group, Inc. (NYSE: GS).
Under the terms of the deal, the company’s existing shareholders will continue to maintain a significant control position.
Renal Ventures Management intends to use the capital to fund growth initiatives including additional treatment center acquisitions, de novo center openings and expansion into related services.
In addition to the investment, the company has completed syndication of a senior credit facility with J.P. Morgan Chase & Co. (NYSE: JPM), and Vectra Bank Colorado, N.A., to provide the company with additional capital for growth and operations.
Founded in 1997 and led by CEO Larry Chatfield, Renal Ventures Management provides long-term delivery of dialysis care to patients suffering from kidney failure, or end-stage renal disease. The company owns and operates centers in New Jersey, Pennsylvania, West Virginia, Iowa, Arkansas and Texas and operates an infusion therapy company located in Lakewood.